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ABSTRACT 
Background 
Completion rates for medication therapy management (MTM) services have been lower 
than desired and the Centers for Medicare and Medicaid Services has added MTM 
comprehensive medication review (CMR) completion rates as a Part D plan star 
measure. Over half of plans utilize community pharmacists via contracts with MTM 
vendors.  
Objectives 
The primary objective of this survey study was to identify factors associated with the 
CMR completion rates of community pharmacies contracted with a national MTM 
vendor.  
Methods 
____________________________________________________
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Representatives from 27,560 pharmacy locations contracted with a national MTM 
vendor were surveyed. The dependent variable of interest was the pharmacies’ CMR 
completion rate. Independent variables included the pharmacy’s progressiveness 
stratum and number of CMRs assigned by the MTM vendor during the time period, as 
well as self-reported data to characterize MTM facilitators, barriers, delivery strategies, 
staffing, selected items from a modified Assessment of Chronic Illness care, and 
pharmacist/pharmacy demographics. Univariate negative binomial models were fit for 
each independent variable, and variables significant at p < 0.05 were entered into a 
multivariable model. 
 
Results 
Representatives from 3836 (13.9%) pharmacy locations responded; of these, 90.9% (n 
=3486) responses were usable. The median CMR completion rate was 0.42. Variables 
remaining significant at p < 0.05 in the multivariable model included: progressiveness 
strata; pharmacy type; scores on the facilitators scale; responses to two potential 
barriers items; scores on the patient/caregiver delivery strategies sub-scale; providing 
MTM at multiple locations; reporting that the MTM vendor sending the survey link is the 
primary MTM vendor for which the respondent provides MTM; and the number of hours 
per week that the pharmacy is open. 
 
Conclusions 
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Factors at the respondent (e.g., responses to facilitators scale) and pharmacy (e.g., 
pharmacy type) levels were associated with CMR completion rates. These findings 
could be used by MTM stakeholders to improve CMR completion rates. 
Keywords 
Community pharmacy services, Medication therapy management, Health care surveys, 
Medicare 
 
INTRODUCTION 
The Medicare Part D prescription drug benefit was created through passage of the 
Medicare Modernization and Improvement Act in 2003 and implemented in 2006.1 In 
2018, more than 43 million Medicare beneficiaries (72%) elected to receive prescription 
drug coverage through Part D.2 The prevalence, complexity, and expense of medication 
use among Medicare beneficiaries continues to grow.3  
 
Medication therapy management (MTM) is proposed as a strategy for optimizing 
medication use among Medicare beneficiaries and was intended to improve medication 
adherence while reducing adverse drug events.1  All stand-alone Medicare Part D 
prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA-
PDs) are required to offer MTM services to beneficiaries meeting general criteria: 
having 2 to 3 chronic conditions, taking 2 to 8 Part D medications, and a likelihood of 
exceeding $4,044 in annual Part D medication costs.4 Plans’ specific criteria can be 
less, but not more, restrictive.4 Eligible beneficiaries must be offered a comprehensive 
medication review (CMR) annually as a part of MTM.4 
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Over the last several years, the Centers for Medicare and Medicaid Services (CMS) has 
expressed concern with lower than expected patient volumes receiving MTM services 
and has introduced changes to expand patient access to these services, such as the 
requirement for “opt-out” vs. “opt-in” MTM enrollment and strategies to enhance 
beneficiary awareness of MTM.5  To promote access further, completion rates for CMRs 
were added as a star measure for Part D plans in 2016.6 The Star Ratings program 
assesses plans on several measures and provides a rating ranging from 1 to 5 stars, 
with 5 being the highest rating.7 Plans are incentivized to improve their star ratings. For 
example, if a plan successfully achieves a 5 star rating, then CMS permits beneficiaries 
to change to the plan outside of open enrollment periods.7 In addition, MA-PDs with 4 or 
more stars receive quality bonus payments to enhance services for beneficiaries.7 
Although the plans are rated by CMS, community pharmacies providing MTM services 
are not. Rather, community pharmacies focus on ensuring positive contributions toward 
plans’ star ratings in order to secure their inclusion in the plans’ preferred provider 
networks and reduce their direct and indirect remuneration fees.8 Several star 
measures, including CMR completion rates, can be positively influenced by community 
pharmacists.7  
 
In 2018, 65.6% of plans utilized MTM vendor-contracted community pharmacists to 
provide MTM services.9 Therefore, identifying strategies used by contracted community 
pharmacies that drive CMR completion rates has important implications for pharmacy 
practice and MTM policy. Recent literature has explored the effect of scripted language 
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use, varying approaches to patient outreach, and incentives and education for 
pharmacists.10-13 These and other potential drivers of CMR completion warrant further 
study. 
 
Objectives 
The primary objective of this survey study was to identify factors associated with the 
CMR completion rates of community pharmacies contracted with a national MTM 
vendor. Secondary objectives were to characterize MTM barriers, facilitators, delivery 
strategies, and pharmacy staff roles in MTM delivery. 
 
METHODS 
 
Conceptual Framework 
As described above, Medicare Part D MTM eligibility criteria focuses on those with 
chronic conditions.4 The Chronic Care Model (CCM) describes six elements that 
positively influence care for the chronically ill.14-15 These elements align well with MTM 
delivery (e.g., patient self-management support through the provision of personal 
medication lists and medication-related action plans). Therefore, the CCM was applied 
to the design of this study. The Assessment of Chronic Illness Care (ACIC) is a 
quantitative survey instrument designed to assist practices in evaluating the extent to 
which care aligns with CCM elements.16-17 As part of the study team’s prior research 
examining MTM delivery within the framework of the CCM, the ACIC was modified for 
application to MTM.18 
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Study Design and Population 
This cross-sectional study utilized data from two sources: a national survey of 
pharmacists representing community pharmacies contracted by an MTM vendor and 
data provided by the MTM vendor. The MTM vendor created a de-identified listing of all 
40,552 pharmacies nationally contracted to provide MTM services, as of 5/1/15, with the 
“practice environment progressiveness” strata (described below) for each pharmacy’s 
location indicated. To avoid duplicate responses and ensure respondent involvement in 
MTM, the pharmacist accessing the most MTM cases (as determined by the MTM 
vendor) was eligible to complete the survey on behalf of their pharmacy. If a pharmacist 
was identified as accessing the most MTM cases for more than one pharmacy, one 
pharmacy location from the “group” was randomly selected by the MTM vendor and that 
respondent was asked to consider the survey items with only the selected pharmacy in 
mind. A total of 27,560 pharmacy locations were surveyed. 
 
Study Measures 
Dependent Variable. The dependent variable was the “CMR completion rate” for each 
pharmacy. This was defined as the proportion of all CMRs assigned to the pharmacy 
that were completed, computed for the period of 5/1/15 to 4/30/16 from data provided by 
the MTM vendor. All CMRs, regardless of payer (Medicare Part D or other MTM payer) 
were included, and the payer for CMRs was unknown to investigators. 
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Independent Variables. Independent variables included self-reported survey data to 
characterize MTM facilitators, MTM barriers, MTM delivery strategies, and self-reported 
data related to MTM staffing, selected items from the modified ACIC,18 respondent 
(pharmacist) demographics, and pharmacy demographics. Additional independent 
variables included the pharmacy’s progressiveness stratum (described below), and 
number of CMRs assigned by the MTM vendor to the pharmacy during the time period. 
These variables were provided by the MTM vendor. 
 
Survey Development 
Informed by the study team’s prior qualitative work,18 survey items were generated to 
assess MTM facilitators, barriers, and delivery strategies for each element of the 
CCM.14-15 Items were pilot tested for clarity and time estimates by three MTM experts 
nationally and six local community pharmacy residents and preceptors. The final survey 
(≤ 127 items total, with skip patterns applied) consisted of six total sections (Appendix 
1.)19  
 
The first section (33 items, divided into three sub-sections) included 17 MTM facilitator 
items (i.e., section 1a; pages 1-4 in Appendix), 7 MTM barrier items, and 9 MTM 
delivery strategy items. These items were assessed using 5-point Likert-type scales 
anchored with 1=never and 5=always. The second section included items assessing the 
extent to which specific types of pharmacy staff were employed at the pharmacy (data 
not shown). The third section contained 12 items from the modified ACIC, scored on a 0 
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to 11 point scale with responses indicating varying levels of agreement with the extent 
to which CCM elements are integrated into MTM delivery.  
 
As described previously,18 modifications were made with permission from the original 
ACIC developers to improve relevance to MTM. The 12 items were selected based on 
interquartile ranges, item-total correlations, and qualitative findings from prior work.18 
The fourth and last section contained 19 items assessing respondent and pharmacy 
demographic data.  
 
Practice Environment Progressiveness Strata Development 
To control for the external environment (e.g., state laws and MTM payer mix) which was 
identified as an important consideration in this study team’s prior qualitative work,18 
states were stratified by “practice progressiveness.” The strata were defined as Low, 
Moderate, and High, based on: a) the scope of practice in each states’ pharmacy 
practice act (e.g., whether pharmacists could initiate therapy under collaborative 
practice agreements); b) MTM payer mix; and c) whether an MTM pharmacist provider 
network was active. Information, as of 2015, was obtained from the National Alliance of 
State Pharmacy Associations and various state association and other professional 
websites. Draft strata were reviewed and modified based on input from four national 
MTM experts. After finalizing the assignment of states to strata, the MTM vendor 
provided the stratum designated for each de-identified pharmacy. 
 
Data Collection 
9 
 
Pharmacists were invited by emails sent by the MTM vendor in July 2016 to participate 
in the survey, which was administered using REDCap.23 To enhance the response rate, 
three follow-up emails were sent by the MTM vendor at weekly intervals. Using a unique 
survey code provided in the invitation, survey responses were linked to the pharmacy’s 
CMR completion rate (computed as described above) as well as the pharmacy’s 
“practice environment progressiveness” stratum from data provided by the MTM vendor. 
As an incentive, respondents had the option to enter a gift card drawing. This study was 
approved by the institutional review board. 
 
Data Analysis 
Responders were defined as unique survey attempts with at least one answered 
question. Usable surveys were a) those with answers provided for at least 12 of the 17 
MTM facilitators items and b) linkable to outcome (i.e., CMR completion) data. If 
multiple attempts were submitted for the same survey code, the first attempt was used if 
both attempts were complete. If one attempt was complete and one incomplete, data 
from the complete attempt were used. The first response for a given item was used 
when multiple incomplete attempts were recorded.  
 
Non-responders included those pharmacies that did not complete a survey and 
pharmacies belonging to a group of pharmacies but not selected at random (see above) 
to be surveyed. How the pharmacies were grouped was not available to the study team. 
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Respondent characteristics and pharmacy staff roles in MTM. To characterize 
respondents and reported roles in MTM, descriptive statistics (medians, 25th/75th 
percentiles, frequencies) were computed. Medians and percentiles were calculated for 
numerical variables because many were non-normal (skewed to left or right), including 
CMR completion rate. Differences in demographics across strata were evaluated using 
Kruskal-Wallis and Chi-squared tests. 
 
Scale structure. The construct validity for each scale (sections 1 and 3, as described 
above) was estimated using principal components analysis computed with all available 
responses, regardless of linkage to outcome data. Scale structure was determined 
through examination of component loadings and scree plots. Cronbach’s alpha was 
then computed for each identified sub-scale to estimate internal consistency. Analyses 
were performed using SPSS version 24.21 
 
Responses to scale items. Data from scales with more than two items were included if 
at least 67% of the items were completed, and data from scales with only two items 
were included if at least 50% of the items were completed. Within-respondent means for 
completed scale items were imputed for missing data on each scale when the minimum 
number, but not all, of the items were completed. Descriptive statistics (medians, 
25th/75th percentiles, frequencies) were computed to summarize scale responses. Two 
barriers items were reverse-scored so that higher values consistently indicated more 
positive responses. 
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CMR completion. Univariate negative binomial models were fit for each independent 
variable and variables significant at p < 0.05 were entered into a multivariable model. In 
the negative binomial models, number of CMRs completed was the outcome variable 
with number of CMRs assigned (on the natural log scale) included in the model as an 
offset. The offset term accounts for the fact that different pharmacies had different 
numbers of CMRs assigned within the specified time period. This allowed for the 
modeling of the appropriate rate. Non-response bias was assessed by comparing CMR 
completion rates for pharmacies with outcome data able to be linked to survey data to 
rates from pharmacies with outcome data that were not linked to survey data using a 
negative binomial which included strata as a covariate. These modeling analyses were 
performed in SAS version 9.4.22  
 
 
RESULTS 
 
Respondent Characteristics and Pharmacy Staff Roles in MTM 
Representatives from a total of 3836 pharmacy locations out of 27,560 pharmacy 
locations surveyed responded and completed at least one question (response rate, 
13.9%); of these, 90.9% (n =3486) responses were usable (Figure 1).  
 
Respondent and pharmacy characteristics by stratum are summarized in Tables 1 and 
2 in order to illustrate demographic differences across strata, reflecting how our strata 
definitions grouped pharmacies with respondent characteristics pertinent to environment 
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progressiveness (e.g., education and training levels).  Responses primarily came from 
managers, owners, and/or full-time pharmacist employees of retail chain or independent 
pharmacies, with more chain responses in the “Low” progressiveness stratum. Most 
respondents were white and female, with a median age of 44 years. About half of the 
total sample completed a PharmD, with a smaller percentage of respondents with a 
PharmD in the “Low” progressiveness stratum. Fewer than 5% of the total sample 
completed a PGY-1 residency and fewer than a quarter completed an MTM certificate 
program, and each of these credentials was more common among respondents in the 
“High” progressiveness stratum. There were no significant differences in respondents’ 
year first licensed among the three strata. Respondents reported having a median 4 
hours per week dedicated to MTM activities. Response bias was evident. Among all 
40,551 pharmacies contracted to provide MTM in this study that were assigned at least 
one CMR opportunity, the CMR completion rate was 48% higher among responders vs. 
non-responders. No meaningful differences in pharmacy staff role utilization in MTM 
were observed; therefore, these data are not shown.  
 
Scale Structure 
 
 
Facilitators, Delivery Strategies, and ACIC Scales 
Principal components analyses identified one-component solutions for the MTM 
facilitators and modified ACIC items, with Cronbach alpha internal consistency 
estimates of 0.90 and 0.95, respectively. Therefore, the items assessing facilitators 
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were combined into a 17-item scale, and the modified ACIC items were combined into a 
12-item scale. Principal components analysis of the items related to delivery strategies 
identified a 3-component solution. The first sub-scale (“patient/caregiver delivery 
strategies”) contained 5 items (alpha, 0.73). The second sub-scale (“documentation 
strategies”) contained 2 items (alpha, 0.63). The third sub-scale (“clinical information 
strategies”) contained 2 items (alpha, 0.62). All scale scores were computed as a mean 
of individual item scores.  
 
The median score on the MTM facilitators scale was 3.82 (range, 1 to 5.) Of the 17 
items comprising the facilitators scale, only 2 items were assessed positively (i.e., a 
response of “often” or “always”) in fewer than 50% of the sample. These items included: 
“Physicians and other prescribers are responsive to patient care recommendations I 
make as part of MTM” and “There is written material on community resources available 
for my patients.” The median score on the patient/caregiver delivery strategies sub-
scale was 4.20 (range, 1 to 5), and all items were assessed positively by 50% or more 
of respondents. The median score on the documentation strategies sub-scale was 3.50 
(range, 1 to 5) and both items were assessed positively by 50% or more of respondents. 
The median score on the clinical information strategies sub-scale was 2.50 (range, 1 to 
5) and both items were assessed positively by fewer than 30% of the sample. The mean 
(sd) modified ACIC score was 4.84 (2.37). 
 
Barriers Items 
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Because items related to barriers did not cluster into a meaningful scale or sub-scales in 
the principal components analysis, each barrier item was analyzed individually for 
association with CMR completion. Median scores on MTM barriers items ranged from 2 
to 5, with most items assessed positively by at least 50% of respondents, indicating that 
the barriers presented on the survey were generally not problematic, with two 
exceptions. One exception was for the item: “I have ready access to laboratory or other 
patient-specific clinical data.” Most (85%) respondents indicated this as occurring 
“never”, “rarely”, or “sometimes.” Another exception was for the item: “They [decision 
support functions] are my primary source for identifying medication-related problems 
during MTM.” Most (74%) respondents indicated this as occurring “often” or “always” 
which was a negative finding because this item had been reverse-scored. The item was 
reverse-scored due to the study team’s a priori decision to consider pharmacist use of 
decision support as a secondary, rather than primary, source in problem identification 
the preferred strategy for MTM delivery. Therefore, reliance on decision support as the 
primary source for problem identification was considered a barrier. 
 
CMR Completion 
Overall, the median CMR completion rate was 0.42 for all responders vs. 0.23 for non-
responders. The following variables were associated (p < 0.05) with CMR completion in 
the univariate modeling: stratum of practice progressiveness, respondent age, year first 
licensed, type of pharmacy, scores on the facilitators scale, all barriers items except for 
the item regarding decision support as the primary source for identifying medication-
related problems, scores on the patient/caregiver and clinical information delivery 
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strategies sub-scales, ACIC scores, number of pharmacy resident FTEs involved in 
MTM, year respondent was first employed at the pharmacy, reported number of hours 
per week the respondent has dedicated to MTM, providing MTM at multiple locations 
(versus at a single location), reporting that the MTM vendor sending the survey link is 
the primary vendor for which the respondent provides MTM, and the number of hours 
per week the pharmacy is open. Respondent age and year first licensed were highly 
correlated (p < 0.0001); therefore, only year first licensed was included in the 
multivariable model.  
 
Variables remaining significant at p < 0.05 in the multivariable model (Table 3) included: 
practice progressiveness strata; type of pharmacy; scores on the facilitators scale; 
responses to the potential barriers item “Within the organization where I work, people 
without pharmacy training make decisions about my role in MTM”; responses to the 
potential barriers item “They [decision support functions] are clinically important and/or 
relevant”; scores on the patient/caregiver delivery strategies sub-scale; providing MTM 
at multiple locations; reporting that the MTM vendor sending the survey link is the 
primary MTM vendor for which the respondent provides MTM; and the number of hours 
per week that the pharmacy is open. 
 
DISCUSSION 
This survey study identified factors at the respondent level (e.g., responses to some 
facilitators, barriers, and delivery strategy items) and pharmacy level (e.g., stratum 
where pharmacy located, type of pharmacy) that were associated with CMR completion 
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rates among community pharmacies contracted with a national MTM vendor. 
Respondents in “High” progressiveness states reported more advanced pharmacy and 
MTM training than did respondents in less progressive states. This was expected given 
that strata development was informed by the MTM opportunities available in the state, 
which could result in either more pharmacists from these states trained in MTM or an 
ability for employers in these states to recruit pharmacists with these credentials.  
Although it was hypothesized that increased progressiveness would align with higher 
CMR completion rates, it was found that pharmacies in “Low” progressiveness states 
had the highest CMR completion rates. This could be related to our findings pertaining 
to respondents’ primary MTM vendor. When controlling for other variables in the 
multivariable model, respondents who indicated that the MTM vendor providing the 
survey was the primary MTM vendor for which they complete MTM activities had a 9% 
higher CMR completion rate than respondents who completed MTM primarily by 
another vendor. A more diverse payer mix with MTM cases assigned from multiple MTM 
vendors or other regional payers might have resulted in a lesser emphasis on 
completion of CMR opportunities received from this vendor.  
 
The extent (i.e., number of FTEs) to which support staff were utilized in MTM delivery 
was not associated with CMR completion. We also examined the ways in which support 
staff were utilized across progressiveness strata and no meaningful differences were 
observed. These findings were surprising and merit further research given increasing 
emphasis on the utilization of pharmacy technicians, student pharmacists, and others in 
MTM provision.23-25 
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These findings point to specific respondent-level behaviors that could be considered by 
community pharmacies, regardless of their practice environment, MTM vendors, and 
payers wishing to improve CMR completion rates. For every unit increase in score on 
the facilitators scale, a 15% increase in CMR completion rate was found. While 
responses to the facilitators scale were overall positive, these findings suggest there is 
room for improvement in areas such as prescriber relationships and having information 
about community resources available. This supports prior literature identifying 
prescriber-pharmacist relationships as a barrier in MTM.26-27 Various strategies for 
improving these relationships have been suggested such as the pharmacist being the 
initiator of relationships, building trust through provision of high quality patient care 
recommendations, providing education to physicians on the pharmacist’s role, and 
utilizing facsimile while exploring other prescriber-preferred methods to communicate 
recommendations.28-30 Similarly, prior work has found that referrals to community 
resources as part of MTM are uncommon18 and that opportunities to enhance 
collaborations between community pharmacies and other community-based 
organizations is evident.31 The use of scripted language for introducing/explaining MTM 
also is addressed by one of the items in the facilitators scale. The positive association 
between using such language and CMR completion is consistent with recent research 
findings.10 
 
For every unit increase in score on the patient/caregiver delivery strategies sub-scale, 
an 11% increase in the CMR completion rate was observed. This sub-scale included 
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behaviors such as providing patients with flexible options for MTM delivery (e.g., 
telephone, video-conferencing), engaging caregivers, and supporting patient self-
management. Again, while scores on this sub-scale were positive overall, community 
pharmacies could examine their MTM delivery to ensure their practice, when permitted 
by the MTM vendor/payer, aligns with these items because doing so would be expected 
to positively contribute to CMR completion. These findings support existing literature 
suggesting that strong patient self-management strategies are evident in MTM 
services,18 and patients are receptive of services delivered via video-conferencing.32 
 
The relationship between specific barriers items and CMR completion was unexpected. 
For example, for every unit increase on the item, “Within the organization where I work, 
people without pharmacy training make decisions about my role in MTM,” a 2% 
increase in CMR completion rate was found. The opposite was anticipated—that 
leadership structures wherein pharmacists oversee MTM provision would be associated 
with higher levels of CMR completion. However, this finding might emphasize the role of 
those trained in management, industrial engineering, or other fields in driving pharmacy 
performance on MTM quality measures such as CMR completion. It was also surprising 
that for each unit increase on the item “They [decision support functions] are clinically 
important and/or relevant,” CMR completion rate decreased by 4%. However, it is 
possible that this is indicative of longer time spent (and consequently, fewer MTM cases 
completed) when the decision support functions are valued highly by the pharmacist. 
Additionally, previous research has found that less experienced pharmacists appear to 
rely more heavily on decision support in MTM;18 therefore, other unmeasured 
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confounders indicating less respondent experience and/or confidence in MTM delivery 
among those placing greater importance on decision support could be reducing their 
completion of CMRs. 
 
These findings highlight opportunities for further research, because CMR completion 
does not provide information about the quality of the CMR provided. Given an 
increasing emphasis by CMS on value-based care and payment models,33 there is a 
critical need for stakeholder engagement in defining “high quality” MTM. This has 
implications for CMS in the consideration of future star measures, as well as for MTM 
vendors and community pharmacies in the development of pharmacist training and 
reimbursement structures. 
 
Finally, the number of CMR opportunities assigned to the pharmacy by the vendor was 
considered. It is reasonable to expect that a pharmacy with more CMR opportunities 
would be more likely to complete CMRs, because the business case for making 
necessary staffing and workflow changes to support service provision would be 
stronger. However, an association between CMR cases assigned and CMR completion 
rates was not found and therefore the number of CMR opportunities assigned was not 
included in the multivariable model. Further research should explore the lack of 
association between case volume and completion rates. 
 
Limitations 
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This study has limitations. First, response bias is evident indicating that those 
completing the survey were overall more engaged in MTM given their higher CMR 
completion rates compared to non-responders. Moreover, many respondents stopped 
the survey early and missing data was pervasive. Even with a low response rate, the 
sample size in this study was large, and so statistical significance does not imply clinical 
importance. However, in spite of the low response rate and evidence of response bias, 
the sample closely mirrored the distribution of community pharmacy types nationally. An 
analysis of community pharmacies nationally in 2015 found that 61.5% were chain 
(when combining retail, mass merchant, and grocery store), 34.8% were independent, 
and 2.8% were “clinic” pharmacies.34  
 
In addition, while survey items were generated from prior qualitative research and 
underwent pilot testing, some of the scales’ reliability estimates were lower than desired 
and barriers items could not be measured as a scale. These findings might also have 
been influenced by the timing of survey administration and the time period over which 
CMR completion was measured. The CMR completion rate was added as a Part D star 
measure in January 2016,6 which was the mid-point of the study’s time period for CMR 
completion rate computation. It is likely that CMR completion following January 2016 
was higher than the prior period due to changing payer priorities. CMR completion was 
also found to be higher among respondents reporting that the MTM vendor who 
partnered with the study team on this survey was the primary MTM vendor for which 
they completed MTM. Findings might have differed had the study team partnered with a 
different MTM vendor.  
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CONCLUSIONS 
This survey study identified factors associated with CMR completion rates among 
community pharmacies contracted with a national MTM vendor. These findings have 
practice and policy implications for a multitude of MTM stakeholders, including 
pharmacists, support staff, management, MTM vendors, and payers. 
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Table 1. Respondent Characteristics, by Progressiveness Strata (Low (L), Moderate (M), High (H) ) 
Respondent characteristics Pairwise differences 
Characteristic Na L 
(n=1217) 
M 
(n=1084) 
H 
(n=1185) 
 
Age in years, median 
(Q25,Q75b) 
2742 44 (35,55) 44 (35,55) 43 (34,54) NS 
Male sex, n (%) 2896 474 (46.79) 419 (46.92) 413 (41.72) p =0.03c; L vs H;  
M vs H 
Caucasian, n (%) 2884 800 (79.52) 646 (72.34) 824 (83.65) p <0.0001c; L vs M; L 
vs H; M vs H 
Ethnicity (Not 
Hispanic/Latino), n (%) 
2840 975 (98.19) 834 (95.42) 950 (97.64) p =0.001c; L vs M; 
M vs H 
PharmD as highest 
pharmacy degree,  
n (%) 
2906 453 (44.63) 494 (54.95) 516 (52.02) p < 0.0001c; L vs M; L 
vs H 
Year first licensed, median 
(Q25,Q75) 
2787 1997 (1986,2008) 1999 (1986,2009) 1999 (1987,2009) NS 
Any additional education, n 
(%) 
2891 159 (15.68) 145 (16.38) 172 (17.34) NS 
Post-graduate year one 
residency, n (%) 
2891 21 (2.07) 26 (2.94) 54 (5.44) p =0.0001c; L vs H; M 
vs H 
Any certifications, n (%) 2880 648 (64.41) 610 (69.00) 692 (69.90) p =0.02c; L vs M; L vs 
H  
MTM certificate (any),  
n (%) 
2880 142 (14.12) 159 (17.99) 206 (20.81) p =0.0004c; L vs H 
Year employed at 
pharmacy, median 
(Q25,Q75) 
2861 2009 (2000,2013) 2010 (2002,2014) 2010 (2004,2014) p =0.003d; L vs. H 
Position, n (%) 2897    p =0.02c; L vs M; L vs 
H 
     Manager/Owner  519 (51.49) 459 (51.23) 506 (50.96)  
     Full-time Pharmacist  418 (41.47) 340 (37.95) 383 (38.57)  
     Resident/Fellow  0 (0.00) 4 (0.45) 1 (0.10)  
     Other  71 (7.04) 93 (10.38) 103 (10.37)  
Hours per week dedicated 
to MTM, median (Q25,Q75) 
2843 3 (2,6) 4 (2,6) 4 (2,6) NS 
Provides MTM at multiple 
locations, n (%) 
2909 985 (96.95) 868 (96.55) 964 (96.98) NS 
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Table 2. Pharmacy Characteristics, by Progressiveness Strata (Low (L), Moderate (M), High (H) ) 
Pharmacy characteristicse Pairwise differences 
Characteristic Na L M H  
Pharmacy type, n (%) 2879    p <0.0001c; L vs M;  
L vs H 
     Retail chain  595 (58.79) 429 (48.58) 508 (51.63)  
     Independently owned  384 (37.94) 396 (44.85) 393 (39.94)  
     Health-system  13 (1.28) 31 (3.51) 48 (4.88)  
     Other  20 (1.98) 27 (3.06) 35 (3.56)  
# of prescriptions filled per 
week, median (Q25,Q75b) 
2817 
1000 (700,1500) 1000 (600,1500) 1000 (700,1600) 
p =0.01d; L vs M;  
M vs H 
Hours pharmacy open per 
week, median (Q25,Q75) 
2857 73 (55,79) 56 (49,76) 59 (50,77) p <0.0001d; L vs M;  
L vs H 
Residency training site, n 
(%) 
2874 65 (6.49) 72 (8.08) 89 (9.07) NS 
Student training site, n (%) 2850 375 (37.69) 353 (39.89) 476 (49.07) p <0.0001c; L vs H;  
M vs H 
FTEs employed, median 
(Q25,Q75)f 
     
     Pharmacists 3138 
 
2.00 (1.25,2.00) 2.00 (1.00,2.00) 2.00 (1.00,2.00) NS 
     Float pharmacists 3141 0.00 (0.00,1.00) 
 
0.20 (0.00,1.00) 0.04 (0.00,1.00) NS 
     Pharmacy technicians 
 
3141 
 
2.00 (1.00,4.00) 
 
2.60 (1.50,4.00) 
 
3.00 (1.75,4.80) 
 
p <0.0001d; L vs M,  
L vs H, M vs H 
     Other personnel 3141 0.75 (0.00,2.00) 0.00 (0.00,2.00) 0.20 (0.00,2.00) p <0.0001d; L vs M; L 
vs H 
FTEs involved in MTM, 
median (Q25,Q75)f 
     
     Pharmacists 
 
2887 
 
1 (1,2) 
 
1 (1,2) 
 
1 (1,2) 
 
p <0.0001d; L > M;  
L > H 
     Pharmacy technicians 2999 0 (0,1) 0 (0,1) 0 (0,1) p =0.03d; L< H 
Survey sent by primary 
MTM vendor, n (%) 
2860 749 (75.28) 616 (69.60) 593 (60.51) p <0.0001c; L vs M;  
L vs H; M vs H 
 % of MTM provided under 
Part D, median (Q25,Q75) 
2782 90 (70,100) 90 (70,100) 85 (65,100) NS 
CMR completion rate, 
median (Q25,Q75)g 
3486 0.44 (0.25,0.64) 0.40 (0.20,0.61) 0.41 (0.21,0.63) p = 0.001d; L vs M;  
L vs H 
a Refers to number of non-missing responses received for variable 
b Q25 = 25th percentile, Q75 = 75th percentile 
c Chi-squared test 
d Kruskal-Wallis test 
e Self-reported by respondent as part of survey  
f Only reported for FTE roles where 75th percentile > 0 
g Computed from data provided by MTM vendor 
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Table 3. Final Multivariable Model (n=2492) Predicting CMR Completion Rate 
Variablea Rate Ratio Standard 
Error 
Rate Ratio Chi-
Square 
(df) 
Pr > ChiSq 
Confidence 
Limits 
Strata 
     Low vs. High progressive 
     Moderate vs. High progressive 
 
1.02 
0.94 
 
0.03 
0.03 
 
0.95 
0.88 
 
1.08 
1.00 
6.51 
(2) 
0.04 
Type of Pharmacy 
     Independent vs. chain (any) 
     Health-system vs. chain (any) 
     Other vs. chain (any) 
 
0.94 
0.74 
0.84 
 
0.03 
0.07 
0.07 
 
0.88 
0.61 
0.70 
 
1.01 
0.88 
0.99 
14.84 
(3) 
< 0.01 
Facilitators scaleb 1.15 0.04 1.07 1.23 16.69 
(1) 
< 0.01 
MTM decision makerc 1.02 0.01 1.00 1.05 4.20 
(1) 
0.04 
Relevance of decision supportd 0.96 0.02 0.92 1.00 4.45 
(1) 
0.04 
Patient/caregiver delivery 
strategies subscalee 
1.11 0.03 1.04 1.17 11.09 
(1) 
< 0.01 
Provides MTM at multiple 
locations 
1.78 0.26 1.34 2.35 14.39 
(1) 
< 0.01 
Vendor sending survey is primary 
vendor for which respondent 
completes MTM 
1.09 0.03 1.03 1.15 8.09 
(1) 
< 0.01 
Hours pharmacy open per weekf 0.98 0.01 0.95 0.99 10.83 
(1) 
< 0.01 
a: Also included but not significant: Year first licensed as a pharmacist in any state; responses to the following 
potential barrier items, measured on scale where 1=never, 2=rarely, 3=sometimes, 4=often, 5=always: “After 
completing an MTM activity, I can easily identify patients for follow up when clinically appropriate.”, “I have ready 
access to laboratory or other patient-specific clinical data.”, “They [patients] understand the difference between MTM 
and the care they receive during prescription processing/patient counseling.”, “They [patients] are able to use the 
personal medication record (PMR) and medication action plans (MAP) we provide (as applicable) successfully for 
self-management.”; clinical information delivery strategies sub-scale (2 items); responses to the Assessment of 
Chronic Illness Care scale (12 items); number of pharmacy resident FTEs involved in MTM; years employed at 
pharmacy; and hours per week respondent has dedicated to MTM activities. 
b: Responses to potential MTM facilitators scale, measured on scale where 1=never, 2=rarely, 3=sometimes, 
4=often, 5=always (17 items including: “With regards to the MTM documentation platform I use for most of my MTM 
activities (5 items): ‘Sufficient training is provided (by pharmacy and/or platform vendor’; ‘It functions as intended 
without a need for “workarounds” or extra steps,’ ‘Patient information is shared, or integrated with, my dispensing 
software,’ ‘It flags and describes problems in a comprehensive manner so I am comfortable acting quickly on 
identified problems,’ ‘It facilitates effective communication with other healthcare providers.’”; “With regards to the 
pharmacy organization where I am employed (5 items): ‘MTM workflow is clearly defined for all pharmacy staff,’ ‘A 
formal quality assurance process is used to ensure high quality MTM is delivered,’ ‘Staff skills in patient self-
management are emphasized during hiring and/or training,’ ‘Organizational goals for MTM delivery are clear and 
management is supportive of my participation in MTM,’ ‘Organizational resources (e.g., IT support, billing assistance) 
are available for MTM when needed and provided in a timely manner.’”; “With regards to the work culture at my 
pharmacy (4 items): ‘My colleagues and I use standard and/or scripted language for introducing/explaining MTM to 
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patients,’ ‘A friendly work “culture” with positive working relationships among pharmacists and staff is exhibited at my 
pharmacy,’ ‘Positive relationships with patients are promoted by pharmacy staff,’ ‘Clinical training and/or continuing 
education opportunities related to MTM are provided when needed.’”; “With regards to communications with 
prescribers and referrals (3 items): ‘Physicians and other prescribers are responsive to patient care recommendations 
I make as part of MTM,’ ‘I am prepared to refer my patients to a specific community resource (e.g., patient 
assistance, diabetes counseling, social worker) if needed,’ ‘There is written material on community resources 
available for my patients.’” ) 
c: Responses to potential barriers item “Within the organization where I work, people without pharmacy training make 
decisions about my role in MTM” measured on scale where 1=never, 2=rarely, 3=sometimes, 4=often, 5=always and 
reverse scored for analysis 
d: Responses to potential barriers item “They [decision support functions] are clinically important and/or relevant” 
measured on scale where 1=never, 2=rarely, 3=sometimes, 4=often, 5=always 
e: Responses to patient/caregiver delivery strategies sub-scale items: “When permitted by payer, patients have 
options for how to be engaged in MTM activities at my pharmacy (e.g., in person, by phone, videoconferencing, etc.)”, 
“When clinically appropriate (e.g., patient is cognitively impaired), I engage caregivers in MTM activities,” “I provide 
positive reinforcement of appropriate patient self-management behaviors”, “I clearly communicate therapy goals to 
patients,” and “My colleagues and I use multiple approaches and/or points of contact for engaging patients and/or 
following up on no shows for MTM appointments,” measured on scale where 1=never, 2=rarely, 3=sometimes, 
4=often, 5=always. 
f: Rate ratio reported is for each 10 hour increase in store hours 
 
 
Figure 1. Survey Enrollment 
De-identified List of Pharmacies from MTM Vendor: 
n= 40,552 
 
 
Total Number of Pharmacies Surveyed: 
 
 
 
n= 27,560  
Total Number of Survey Attempts: 
   n=4967 
 
 
 
 
Total Number of Survey Attempts with Unique ID or No ID Entered AND at Least 1 Question Answered 
   n=3959 
 
 
 
 
Total Number of Survey Attempts with Unique ID AND at Least 1 Question Answered 
   n=3836 
 
 
 
Usable Cohort  
(unique ID with at least 12 of 17 facilitator items answered and linkable to outcome data) 
n=3486 
Duplicate ID entered n=878 
No questions answered n=130 
No ID entered n=123 
Unique ID cannot be linked to 
outcome data n=109 
Did not respond to 12 of 17 facilitator 
items n=241 
 
Single pharmacy locations n=25,192 
Pharmacy groups n=2,368 
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Section 1a: MTM items -Potential MTM Facilitators 
Please indicate the frequency by which the following occur with regards to MTM delivery at 
your pharmacy. 
 
For the following questions, please read each question starting with the statement below: 
 
 
With regards to the MTM DOCUMENTATION PLATFORM I use for most of my MTM ACTIVITIES... 
 
1. Sufficient TRAINING is provided (by pharmacy and/or 5= Always 
platform vendor.) 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
2. It FUNCTIONS as intended without a need for 5= Always 
"workarounds"  or extra steps. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
3. PATIENT INFORMATION is shared, or integrated with, my 5= Always 
dispensing software. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
4. It FLAGS AND DESCRIBES PROBLEMS in a comprehensive 5= Always 
manner so I am comfortable acting quickly on 4= Often 
identified problems. 3= Sometimes 
2= Rarely 
1= Never 
 
5. It facilitates effective COMMUNICATION with other 5= Always 
healthcare providers. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
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For the following questions, please read each question starting with the statement below: 
With regards to the PHARMACY ORGANIZATION WHERE I AM EMPLOYED... 
1. MTM WORKFLOW is clearly defined for all pharmacy 5= Always 
staff. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
2. A FORMAL QUALITY ASSURANCE process is used to ensure 5= Always 
high quality MTM is delivered. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
3. Staff SKILLS IN PATIENT SELF-MANAGEMENT are 5= Always 
emphasized during hiring and/or staff training. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
4. Organizational goals for MTM DELIVERY are clear and 5= Always 
management is supportive of my participation in MTM. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
5. ORGANIZATIONAL RESOURCES (e.g., IT support, billing 5= Always 
assistance) are available for MTM when needed and 4= Often 
provided in a timely manner. 3= Sometimes 
2= Rarely 
1= Never 
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For the following questions, please read each question starting with the statement below: 
With regards to the WORK CULTURE at my pharmacy... 
1. My colleagues and I use STANDARD AND/OR SCRIPTED 5= Always 
LANGUAGE for introducing/explaining MTM to patients. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
2. A FRIENDLY WORK "CULTURE" with positive working 5= Always 
relationships among pharmacists and staff is 4= Often 
exhibited at my pharmacy. 3= Sometimes 
2= Rarely 
1= Never 
 
3. POSITIVE RELATIONSHIPS WITH PATIENTS are promoted by 5= Always 
pharmacy staff. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
4. CLINICAL TRAINING AND/OR CONTINUING EDUCATION 5= Always 
opportunities related to MTM are provided when 4= Often 
needed. 3= Sometimes 
2= Rarely 
1= Never 
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For the following questions, please read each question starting with the statement below: 
With regards to COMMUNICATIONS WITH PRESCRIBERS and referrals... 
1. Physicians and other PRESCRIBERS ARE RESPONSIVE to 5= Always 
patient care recommendations I make as part of MTM. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
2. I am PREPARED TO REFER my patients to a specific 5= Always 
community resource (e.g.,  patient assistance, 4= Often 
diabetes counseling, social worker) if needed. 3= Sometimes 
2= Rarely 
1= Never 
 
3. There is WRITTEN MATERIAL on community resources 5= Always 
available for my patients. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
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Section 1b: MTM items- Potential MTM Barriers 
 
Please indicate the frequency by which the following occur with regards to MTM delivery at 
your pharmacy. 
 
1. After completing an MTM activity, I can easily 5= Always 
IDENTIFY PATIENTS FOR FOLLOW UP when clinically 4= Often 
appropriate. 3= Sometimes 
2= Rarely 
1= Never 
 
2. I have ready access to LABORATORY OR OTHER 5= Always 
PATIENT-SPECIFIC CLINICAL DATA. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
3. Within the organization where I work, people without 5= Always 
pharmacy training MAKE DECISIONS about my role in 4= Often 
MTM. 3= Sometimes 
2= Rarely 
1= Never 
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For the following questions, please read each question starting with the statement below: 
 
With regards to the the DECISION SUPPORT FUNCTIONS (i.e., alerts/flags) of the MTM 
documentation platform I use for most of my MTM activities... 
 
1. They are my PRIMARY SOURCE for identifying 5= Always 
medication-related problems during MTM. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
2. They are CLINICALLY IMPORTANT and/or relevant. 5= Always 
4= Often 
3= Sometimes 
2= Rarely 
1= Never 
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For the following questions, please read each question starting with the statement below: 
With regards to PATIENTS receiving MTM... 
1. They UNDERSTAND THE DIFFERENCE between MTM and the 5= Always 
care they receive during prescription 4= Often 
processing/patient counseling. 3= Sometimes 
2= Rarely 
1= Never 
 
2. They are ABLE TO USE THE PERSONAL MEDICATION RECORD 5= Always 
(PMR) AND MEDICATION ACTION PLANS (MAP) we provide 4= Often 
(as applicable) successfully for self-management. 3= Sometimes 
2= Rarely 
1= Never 
 8  
 
 
Section 1c:MTM items- MTM Delivery Strategies 
 
Please indicate the frequency by which the following occur with regards to MTM delivery at 
your pharmacy 
 
1. When permitted by payer, PATIENTS HAVE OPTIONS for 5= Always 
how to be engaged in MTM activities at my pharmacy 4= Often 
(e.g., in person, by phone, videoconferencing, etc). 3= Sometimes 
2= Rarely 
1= Never 
 
2. When clinically appropriate (e.g., patient is 5= Always 
cognitively impaired), I ENGAGE CAREGIVERS in MTM 4= Often 
activities. 3= Sometimes 
2= Rarely 
1= Never 
 
3. I REQUEST PATIENT-SPECIFIC INFORMATION, such as 5= Always 
laboratory data, from other providers to  assist in 4= Often 
patient assessment and problem identification. 3= Sometimes 
2= Rarely 
1= Never 
 
4. When conducting a comprehensive medication  review, I 5= Always 
DOCUMENT most of the encounter in the MTM 4= Often 
documentation platform WHILE SPEAKING with the 3= Sometimes 
patient. 2= Rarely 
1= Never 
 
5. I measure patient VITAL SIGNS (e.g., blood pressure, 5= Always 
pulse) and perform physical assessment  within my 4= Often 
scope of practice as part of my MTM activities. 3= Sometimes 
2= Rarely 
1= Never 
 
6. I provide positive reinforcement of appropriate 5= Always 
PATIENT SELF-MANAGEMENT behaviors. 4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
7. I clearly communicate therapy GOALS  to patients. 5= Always 
4= Often 
3= Sometimes 
2= Rarely 
1= Never 
 
8. I finalize the PERSONAL MEDICATION RECORD (PMR) AND 5= Always 
MEDICATION ACTION PLAN (MAP) (when applicable) 4= Often 
during the MTM encounter and provide it to the 3= Sometimes 
patient to take home at that time. 2= Rarely 
1= Never 
 
9. My colleagues and I use multiple approaches and/or 5= Always 
points of contact for engaging patients and/or 4= Often 
FOLLOWING UP ON "NO SHOWS" for MTM appointments. 3= Sometimes 
2= Rarely 
1= Never 
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Section 2: Summary of MTM Roles at your Pharmacy 
 
Please answer the following questions with regards to staff roles at your primary pharmacy of 
employment. 
 
For the purpose of this survey: 1 FTE=40 hours/week. 
 
Please enter the FTE as an interval using decimals rather then fractions (for example 1/2 of an 
FTE=0.5) 
 
1. Enter the total PHARMACIST FTEs (Full time    
equivalent) employed ON-SITE at your pharmacy. 
 
2. Enter the total number of FLOAT PHARMACIST FTEs                                                                   
utilized at your store. 
 
3. Enter the total number of PHARMACY RESIDENT FTEs                                                             
employed ON-SITE at your pharmacy. 
 
4. Enter the total number of FLOAT PHARMACY RESIDENT    
FTEs utilized at your pharmacy. 
 
5. Enter the total number of pharmacy TECHNICIAN FTEs    
employed on-site at your pharmacy. 
 
6. Enter the total number of pharmacy PAID INTERN FTEs    
employed on-site in a given month at your pharmacy. 
 
7. Enter the total number of PHARMACY IPPE/APPE STUDENTS    
in a given month on-site at your pharmacy. 
 
8. Enter the total number of OTHER PERSONNEL employed    
on-site at your pharmacy. 
 
9. Please provide an explanation of the roles of the    
staff included in the 'OTHER PERSONNEL' category. 
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Please indicate the FREQUENCY in which ON-SITE PHARMACISTS (based at my pharmacy) are 
involved in each step of MTM delivery listed below at your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                       
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total  ON-SITE PHARMACIST FTEs involved in    MTM. 
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Please indicate the FREQUENCY in which FLOAT PHARMACISTS (i.e., those that travel to 
pharmacy to provide MTM) are involved in the following steps of MTM delivery in your 
pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total FLOAT PHARMACIST FTEs involved in    MTM. 
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Please indicate the FREQUENCY in which ON-SITE RESIDENT PHARMACISTS are involved in 
the following steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of ON-SITE PHARMACY RESIDENT    FTEs involved 
in MTM at your pharmacy. 
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Please indicate the FREQUENCY in which FLOAT RESIDENT PHARMACISTS are involved in the 
following steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of FLOAT PHARMACY RESIDENT    FTEs involved 
in MTM at your pharmacy. 
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Please indicate the FREQUENCY in which pharmacy TECHNICIANS are involved in the 
following steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of pharmacy TECHNICIAN FTEs    involved in 
MTM (includes on-site as well as float 
staff). 
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Please indicate the FREQUENCY in which PAID PHARMACY INTERNS are involved in the 
following steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of pharmacy PAID INTERN FTEs    involved in 
MTM at your pharmacy (includes on-site 
as well as float staff). 
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Please indicate the FREQUENCY in which PHARMACY IPPE/APPE STUDENTS are involved in 
the following steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of FTEs PHARMACY IPPE/APPE    STUDENTS 
involved in MTM at your pharmacy (includes 
on-site as well as float staff). 
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Please indicate the FREQUENCY in which OTHER PERSONNEL are involved in the following 
steps of MTM delivery in your pharmacy... 
 
5= Always 4= Often 3= Sometimes 2= Rarely 1= Never 
Introduce and/or explain MTM,                                                                                                                        
schedule patients, and make 
reminder calls. 
 
"Work up" of patients to review                                                                                                                        
medications, identify potential 
medication-related problems, etc. 
Conduct comprehensive                                                                                                                        
medication review and/or 
discussion of targeted medication-related problems with patients. 
 
Documentation and/or billing of                                                                                                                        
MTM activity. 
Follow-up with patient and/or                                                                                                                                                                                                                          
prescribers on medication-related problems. 
 
 
Enter the total number of FTEs OTHER PERSONNEL                                                                  
involved in MTM at your pharmacy (includes on-site 
as well as float staff). 
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Section 3: Select Items from a Modified Assessment of Chronic Illness Care (ACIC) 
 
Please answer the following questions pertaining to your pharmacy's MTM practice as it 
relates to providing care to patients with chronic conditions. These questions are adapted 
from the Assessment of Chronic Illness Care used for primary care practices. Instructions are 
as follows: 
 
1. Answer each question from the perspective of THE PHARMACY ASSOCIATED WITH THE 
SURVEY CODE YOU RECEIVED 
 
2. Answer each question regarding how your organization is doing with respect your 
pharmacy's MTM practice as it relates to providing care for patients with chronic conditions. 
 
3. For each statement, choose the point value that best describes the level of care that 
currently exists in the site. The statements in this section of the survey present key aspects 
of chronic illness care. Each aspect is divided into levels showing various stages in improving 
chronic illness care. The stages are represented by points that range from 0 to 11. The higher 
point values indicate that the actions described on or below the number are more fully 
implemented. 
 
 
1. Organizational Goals for Chronic Care... 0 
1 
2-do not exist or are limited to one condition. 
3 
4 
5-exist but are not actively reviewed. 
6 
7 
8-are measurable and reviewed. 
9 
10 
11-are measurable, reviewed routinely, and are 
incorporated into plans for improvement. 
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2. Linking Patients to Outside Resources... 0 
1 
2-is not done systematically. 
3 
4 
5-is limited to a list of identified community 
resources in an accessible format. 
6 
7 
8-is accomplished through a designated staff 
person or resource responsible for ensuring 
pharmacists/MTM practice staff and patients make 
maximum use of community resources. 
9 
10 
11-is accomplished through active coordination 
between the MTM practice, other providers 
including primary care, community service agencies 
and patients. 
 
3. Assessment and Documentation of Self-Management Needs 0. 
and Activities... 1 
2-are not done. 
3 
4 
5-are expected. 
6 
7 
8-are completed in a standardized manner 
9 
10 
11-are regularly assessed and recorded in 
standardized form linked to a treatment plan 
available to MTM practice, primary care and other 
providers, and patients. 
 
4. Pharmacist/MTM Practice staff Education for Chronic 0 
Illness Care... 1 
2-is provided sporadically. 
3 
4 
5-is provided systematically through traditional 
methods. 
6 
7 
8-is provided using optimal methods (e.g. academic 
detailing). 
9 
10 
11-includes training all practice team members in 
chronic illness care methods such as 
population-based management, and self-management 
support. 
5. Practice Team Functioning... 0 
1 
 
20  
2-is not addressed. 
3 
4 
5-is addressed by assuring the availability of 
individuals with appropriate training in key 
elements of chronic illness care. 
6 
7 
8-is assured by regular team meetings to address 
guidelines, roles and accountability, and problems 
in chronic illness care. 
9 
10 
11-is assured by teams who meet regularly and have 
clearly defined roles including patient 
self-management education, proactive follow-up, 
and resource coordination and other skills in 
chronic illness care. 
 
6. Appointment System... 0 
1 
2-can be used to schedule acute care visits, 
follow-up and preventive visits. 
3. 
4 
5-assures scheduled follow-up with chronically ill 
patients. 
6 
7 
8-are flexible and can accommodate innovations 
such as customized visit length or group visits. 
9 
10 
11-includes organization of care that facilitates 
the patient seeing multiple providers (e.g., 
pharmacist and dietician) in a single visit if 
warranted. 
 
7. Follow-up... 0 
1 
2-is scheduled by patients or pharmacists/MTM 
practice staff in an ad hoc fashion. 
3 
4 
5-is scheduled by the practice in accordance with 
guidelines. 
6 
7 
8-is assured by the practice team by monitoring 
patient utilization. 
9 
10 
11-is customized to patient needs, varies in 
intensity and methodology (phone, in person, 
email) and assures guideline follow-up. 
  
 
8. Registry (list of patients with specific 0 
conditions)... 1 
2-is not available. 
3 
4 
5-includes name, diagnosis, contact information 
and date of last contact either on paper or in a 
computer database. 
6 
7 
8-allows queries to sort sub-populations by 
clinical priorities. 
9 
10 
11-is tied to guidelines which provide prompts and 
reminders about needed services. 
 
9. Feedback... 0 
1. 
2-is not available or is non-specific to the team. 
3 
4 
5-is provided at infrequent intervals and is 
delivered impersonally. 
6 
7 
8-occurs at frequent enough intervals to monitor 
performance and is specific to the team's 
population. 
9 
10 
11-is timely, specific to the team, routine and 
personally delivered by a respected opinion leader 
to improve team performance. 
 
10. Community Programs... 0 
1 
2-do not provide feedback to the MTM practice and 
primary care provider about patients' progress in 
their programs. 
3 
4 
5-provide sporadic feedback at joint meetings 
between the community and MTM practice and primary 
care providers about patients' progress in their 
programs. 
6. 
7 
8-provide regular feedback to the MTM practice and 
primary care provider using formal mechanisms 
(e.g., Internet progress report) about patients' 
progress. 
9 
10 
11-provide regular feedback to the MTM practice 
and primary care provider about patients' 
progress that requires input from patients that is 
then used to modify programs to better meet the 
needs of patients. 
  
 
11. Organizational Planning for Chronic Illness Care... 0 
1 
2-does not involve a population-based approach. 
3 
4 
5-uses data from information systems to plan care. 
6 
7 
8-uses data from information systems to 
proactively plan population-based care, including 
the development of self-management programs and 
partnerships with community resources. 
9 
10 
11-uses systematic data and input from practice 
teams to proactively plan population-based care, 
including the development of self-management 
programs and community partnerships, that include 
a built-in evaluation plan to determine success 
over time. 
 
12. Routine follow-up for appointments, patient 0 
assessments and goal planning... 1 
2-is not ensured. 
3 
4 
5-is sporadically done, usually for appointments 
only. 
6 
7 
8-is ensured by assigning responsibilities to 
specific staff (e.g., pharmacy technician). 
9 
10 
11-is ensured by assigning responsibilities to 
specific staff (e.g., pharmacy technician) who 
uses the registry and other prompts to coordinate 
with patients and the entire practice team. 
  
 
 
 
Section 4: Demographics 
Please answer the following questions to provide basic descriptive data regarding your 
background and the pharmacy where you practice. 
 
Age in Years 
 
Sex Male 
Female 
 
Ethnicity Hispanic/Latino 
Not Hispanic/Latino 
 
Race White/Caucasian 
Check all that apply Black/African-American 
Asian 
American Indian/Alaska Native 
Native Hawaiian or other Pacific Islander 
Other 
 
Pharmacy degree completed B.S. 
PharmD 
Both B.S. and PharmD 
 
Year first licensed as a pharmacist in any state    
(enter as a 4 digit year, i.e. 19_ _) 
 
Additional education/degree completed (check all that PGY-1 residency 
apply PGY-2 residency 
Fellowship 
MBA 
MPH 
M.S. in Pharmacy Practice/Administration 
PhD 
Other 
None 
 
If you answered 'other' to education/ degree                                                                        
completed then please enter additional 
education/degrees 
 
Certifications obtained (check all that apply): Board Certified Pharmacotherapy Specialist (BCPS) 
Board Certified Ambulatory Care Pharmacist 
(BCACP) 
Certified Diabetes Educator (CDE) 
Certified Geriatrics Pharmacist (CGP) 
APhA Pharmacist and Patient-Centered Diabetes 
Care Certificate 
APhA Pharmacy-Based Lipid Management Certificate 
APhA Immunization Certificate 
APhA Medication Therapy Management Certificate 
Other 
None 
 
If you answered 'other' to certifications obtained    
then please enter addititional certifications 
  
 
Primary site of employment Chain retail pharmacy (e.g. CVS, Walgreens, Rite 
Aid) 
Chain mass merchant pharmacy (e.g. Target, 
Walmart) 
Chain grocery store pharmacy (e.g. Kroger, 
Marsh) 
Independent retail pharmacy (fewer than four 
locations) 
Independently-owned chain pharmacy (four or more 
locations) 
Hospital/health-system outpatient pharmacy 
Compounding-only pharmacy 
Other 
 
If you answered 'other' to primary site of employment    
then please enter primary site of employment 
 
Position held at primary site of employment Manager and/or owner 
Full-time pharmacist 
Part-time pharmacist 
Floater/ temporary pharmacist 
Resident/ Fellow pharmacist 
Other 
 
If you answered 'other' to position held at primary                                                                      
site of employment then please enter your current 
position 
 
What year did you start employment at THIS pharmacy    
as a pharmacist? 
(enter as a four digit year, 19_ _) 
 
How many HOURS per week is your time dedicated to MTM    
activities? 
 
Do you provide MTM at multiple locations? Yes 
No 
 
Indicate the number of locations at which you provide    
MTM. 
 
Approximately what PERCENT of MTM activities at THIS    
PHARMACY are for Medicare Part D patients? 
 
Is the MTM vendor who sent you this survey the Yes 
PRIMARY MTM VENDOR for which you complete MTM No 
activities? 
 
Is this pharmacy a training site for pharmacy Yes 
residents? No 
 
Is this pharmacy a training site for pharmacy Yes 
students on introductory and/or advanced pharmacy No 
practice experiences? 
 
Approximately how many prescriptions does your    
pharmacy fill per week? 
 
How many hours a week is your pharmacy open?    
